Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-001299
Filing Date
2025-02-14
Accepted
2025-02-14 17:38:43
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8836
  Complete submission text file 0001172661-25-001299.txt   10533
Mailing Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022
Business Address 510 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10022 (212) 231-4932
ARMISTICE CAPITAL, LLC (Filed by) CIK: 0001601086 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453
Business Address 95 SAWYER ROAD SUITE 110 WALTHAM MA 02453 781-652-4500
Checkpoint Therapeutics, Inc. (Subject) CIK: 0001651407 (see all company filings)

EIN.: 472568632 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89990 | Film No.: 25631331
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)